Background: Small cell lung cancer (SCLC) has high malignancy and high metastasis rate. Ki67 as an antigen for cell proliferation, the higher the ratio, the more active the cancer cells proliferate. The aim of this study was to observe the effect of Ki67 expression on recurrence and prognosis of small cell lung cancer. Method: From July 2013 to July 2014, 91 patients with SCLC were selected. All cases were confirmed by histopathology, and Ki67 immunohistochemical staining showed positive expression. The short-term efficacy was evaluated according to RECIST 1.1. All data were processed by SPSS 19.0 statistical software. The data were expressed by mean standard deviation (x ±s), chi-square test, Pearson linear correlation analysis, Kaplan-Meier method. and Log-rank test, P < 0.05 was statistically significant. Results: In the study group, 47 patients (51.6%) were under 61 years, 44 (48.4%) were males, Smoking index (smoking index ¼ annual x daily smoking) was <¼ 200 for 37 (40.7%) and > 400 for 35 (38.5%). 62 (68.9%) were localized tumor staging. Before chemotherapy of NSE < 11.13 ng / ml was 10 (11%) and > 25 ng/mL was 40 (44%). Ki67 expression index were 14 (15.4%) with over low expression 50-60%, 12 (13.2%) with low expression > 60-70%, 48 (52.7%) with moderate expression > 70-80%, 17 (18.7%) with high expression > 80%.In the study group, 65 patients received treatment, of which 10 (11.0%) were CR, 41 (45.1%) were PR, 13 (14.3%) were SD. Ki67 was statistically significant correlated with smoking (R¼0.265, P¼0.011), tumor stage (R¼0.419，P<0.001), NSE (R¼0.214, P¼0.042) and optimal efficacy (R¼0.244, P¼0.02). The median PFS of low expression, low expression, moderate expression and high expression of Ki67 were 408, 538, 228 and 343 days, respectively (P ¼ 0.042). In particular, when the expression of Ki67 was 70% as the dividing line, ¼ < 70% as the low expression, and > 70% as the high expression, the PFS was 434 days and 261 days, respectively (P¼0. 027). However, there was no significant correlation between Ki67 and OS (2-year survival rate) (P > 0. 05). Conclusion: The lower expression of Ki67 in SCLC is better for drug efficacy, and longer PFS.Ki67 may be one of the predictors of SCLC recurrence. In particular, 70% Ki67 expression index is an important critical index for the progression of small cell lung cancer. In particular, 70% of Ki67 expression index is an important critical index for the progression of SCLC. Keywords: low expression, small cell lung cancer, Ki67 Background: To retrospectively analyze the efficacy and prognostic factors of ectinib hydrochloride alone or combined with brain radiotherapy in the treatment of brain metastases from NSCLC with EGFR mutation, so as to provide a reference for more accurate evaluation of prognosis and selection of the best treatment modality. Method: Total of 85 patients were enrolled from Oct/2014 to Oct/2017 in JLCH who pathologically diagnosed or cytology for NSCLC with EGFR mutations and had developed brain metastases. All the 85 patients were adenocarcinoma. 51 patients received with icotinib combined radiotherapy. 34 patients received with Icotinib alone, 15 patients took loca lesion radiotherapy, 11 patients took whole brain radiation therapy, 25 patients took whole brain radiation therapy and plus dose. SPSS22.0 was applied for survival analysis with Kaplan-Meier method and categorical data with chi-square test. COX model for multiple factors analysis. Logistic method for RR and DCR multi-factor analysis. Results: The total iORR is 64.6%, the iDCR is 95.3%. For the group of icotinib alone, iCR is 5 (14.7%), iPR is 14 (41.2%), iSD is 10 (29.4%), and iPD is (14.7%). iORR is 55.9%, iDCR is 85.2%. For the group of icotinib combined radiotherapy, iCR is 5 (9.8%), iPR is 29 (56.9%), iSD is 17 (33.3%). iORR is 66.7%, iDCR is 100%. There were statistical difference for iDCR between two groups (c 2 ¼7.698, P¼0.022). Logistic model multi-factor analysis results: the surgery history of pulmonary lesion, Update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were PFS independ-ent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were iPFS independent factors. The iDCR of the group of loca lesion radiotherapy, the whole brain radiation therapy and local acceleration were 100%, the iORR is 53.8%, 77.8%, 70.0%. The iDCR of the group of the early involvement of radiotherapy is 100%, the iORR is 77.8%, 46.7%, there were statistical difference between two groups (c 2 ¼4.200, P¼0.040). Conclusion: 1. The use of Icotinib to EGFR mutant NSCLC patients with brain metastases have a higher intracranial objective response rate, prolonged survival significantly. 2. The history of pulmonary lesion surgery, update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and update-GPA grading scale were PFS and iPFS independent factors. 3. The participation of brain radiotherapy can increase iDCR. The early participation of brain radiotherapy can increase iORR. Keywords: Non-small cell lung, brain metastasis, Brain metastasis radiotherapy, Target therapy
Background: To retrospectively analyze the efficacy and prognostic factors of ectinib hydrochloride alone or combined with brain radiotherapy in the treatment of brain metastases from NSCLC with EGFR mutation, so as to provide a reference for more accurate evaluation of prognosis and selection of the best treatment modality. Method: Total of 85 patients were enrolled from Oct/2014 to Oct/2017 in JLCH who pathologically diagnosed or cytology for NSCLC with EGFR mutations and had developed brain metastases. All the 85 patients were adenocarcinoma. 51 patients received with icotinib combined radiotherapy. 34 patients received with Icotinib alone, 15 patients took loca lesion radiotherapy, 11 patients took whole brain radiation therapy, 25 patients took whole brain radiation therapy and plus dose. SPSS22.0 was applied for survival analysis with Kaplan-Meier method and categorical data with chi-square test. COX model for multiple factors analysis. Logistic method for RR and DCR multi-factor analysis. Results: The total iORR is 64.6%, the iDCR is 95.3%. For the group of icotinib alone, iCR is 5 (14.7%), iPR is 14 (41.2%), iSD is 10 (29.4%), and iPD is (14.7%). iORR is 55.9%, iDCR is 85.2%. For the group of icotinib combined radiotherapy, iCR is 5 (9.8%), iPR is 29 (56.9%), iSD is 17 (33.3%). iORR is 66.7%, iDCR is 100%. There were statistical difference for iDCR between two groups (c 2 ¼7.698, P¼0.022). Logistic model multi-factor analysis results: the surgery history of pulmonary lesion, Update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were PFS independ-ent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were iPFS independent factors. The iDCR of the group of loca lesion radiotherapy, the whole brain radiation therapy and local acceleration were 100%, the iORR is 53.8%, 77.8%, 70.0%. The iDCR of the group of the early involvement of radiotherapy is 100%, the iORR is 77.8%, 46.7%, there were statistical difference between two groups (c 2 ¼4.200, P¼0.040). Conclusion: 1. The use of Icotinib to EGFR mutant NSCLC patients with brain metastases have a higher intracranial objective response rate, prolonged survival significantly. 2. The history of pulmonary lesion surgery, update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and update-GPA grading scale were PFS and iPFS independent factors. 3. The participation of brain radiotherapy can increase iDCR. The early participation of brain radiotherapy can increase iORR. Keywords: Non-small cell lung, brain metastasis, Brain metastasis radiotherapy, Target therapy FirstJiLinU, Changchun/CN, 2 First Affiliated Hospital, Jilin University, Changchun/CN Background: Lung adenocarcinoma is an evolutional disease, which includes different stages such as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) , and invasive adenocarcinoma (IA) ,which all can occur independently with each other. However, whether these primary tumors exist synchronous or successively in just one individual. What is the major factor to drive a focus developing from AAH (benigh) to MIA or IA (malignant). In this study, we reported a case with AAH, MIA, and IA to understand and recognize this kind of disease, and to explore the gene heterogeneities among these focuses. Method: XXX, female, 50 years old，non-smoker,whose chest CT suggested two nodules in the right upper lobe, sized 1 cm and 0.5 cm, respectively .Surgical resection in the upper lobe of the right lung was performed for her. Postoperative pathology confirmed that these two nodules were IA and MIA, respectively. Besides those, a third more nodule, which was AAH was found in the deeper resectional lung tissue which had not been found in the chest CT scan. We then performed whole-exome sequencing (WES) to analyze the details of gene information. Results: Sequencing data showed that there was no obvious overlap among these three nodules, we listes the major gene information in Figure 1 . We found that EGFR mutation was just observed in the nodule with IA, but not in MIA or AAH. Conclusion: AAH, MIA, and IA are different evolutional stages of lung adenocarcinoma. Different gene information existing in these different pathologies made them highly heterogenous. EGFR should be the major driver gene which could be observed just in IA, but not in the earlier evolutional stage. More sequencing data is needed to verify our findings. Keywords: heterogenous, Pathology, lung adenocarcinoma, whole-exome sequencing (WES) Background: It's reported that crizotinib response duration time differs among ALK-rearranged NSCLC patients with different ALK fusion patterns and detection methods. However inconsistence existed in some available clinical studies and this heterogeneity in first-line crizotinib treatment laking data to elucidate. Method: 80 ALK-rearranged treatment naïve patients received crizotinib form March 2014 to July 2018 in Hunan Cancer Hospital were enrolled in this study for overall survival data analysis. 56 patients underwent NGS detection (Burning Rock, Guang Zhou, 8 gene panel) were included in the analysis of different ALK fusion partners with crizotinib. 24 patients were detected by ventana. PFS of EML4 or non-EML4 variant, single or multiple variant fusion partners and detection methods were also been evaluated. Results: Among all 80 ALK-rearranged patients treated with crizotinib in first-line, 56 patients (70%) were detected by NGS while 24 patients (30%) were identified by ventana. 16 uncommon variants (18/70, 25.7%) which contained 6 novel fusion variants were detected by NGS. Among 56 NGS-identified ALK-rearranged patients, 13 in 56 (23.2%) patients were found with dual fusion partners and 43 in 56 (86.8%) patients were with exclusive ALK fusion partners in which EML4 was the most commom seen (39 in 43). Especially, dual fusion partners were often observed in patients simultaneously detected carrying variant V3 (8 in 13). The overall response rate in all 80 patients was 88.7% and the median progression-free survival time (mPFS) was 12 months. In subroups analysis of different ALK fusion partterns, patients with exclusive ALK fusion pattern were shown to have a longer PFS than those carrying dual ALK fusion patterns. (12m vs. 6.5m, p ¼ 0.02). Comparing with non-EML4 fusion partners, EML4 fusion partners have the longer PFS (12.0m vs. 6.8m, p¼0.04) . No statistically significant association was observed between the firstline crizotinib efficacy and NGS or ventana detected ALK-rearranged patients (mPFS: 12m VS 16m, P¼0.21). Conclusion: Novel fusion variants and fusion partners can be detected by NGS. Dual fusion pattern coexisted in one ALK-rearranged patients detected by NGS may negatively contribute to first-line crizotinib duration time. Different ALK detection method didn't confer significant heterogeneity in first-line crizotinib efficacy for ALK-rearranged NACLC patients. Keywords: ALK Fusion Partners, Crizotinib, Non-Small Cell Lung Cancer, Next generation sequencing 2 . However, this combination had not been evaluated in the real world, the influential factor of PFS was not sure, and we knew little about the acquired resistance which is of great importance to the subsequent therapy, thus we conducted this study to address these medical needs. Method: A total of 30 advanced EGFR mutant (Del19/L858R) NSCLC patients who received Bevacizumab plus Erlotinib/Gefitinib from March 2014 to July 2017 in Hunan Cancer Hospital were enrolled in this analysis. Clinical information was fully collected. NGS (Burrning rock biotech, 168 genes panel) was applied to detect genetic aberration in both tissue and blood samples, in a dynamic pattern: tissue test before treatment and at progression; blood analysis before treatment, at first radiography evaluation, at the last radiography evaluation before progression and at progression. Results: All patients benefited from this combination. The overall response rate (ORR) was 77% and the median progression survival m(PFS) was 16 months. Neither baseline brain metastasis nor concomitant TP53 mutation shortened PFS (with vs without, 16 m vs 16 m, p¼0.79; 17m vs 13m, p¼0.34). Of EGFR mutation analysis by NGS, the concordant rate was well enough, 70% (21/30) between the paired initial tissue and blood samples. At progression, T790M was defined as the domain acquired resistance mechanism, contributing 43.8%, followed by MET amplification (12.5%), ERBB2 amplification (6.3%), high abundance of SMAD4 mutation (6.3%). Subgroup analysis showed patients with SMAD4 mutation have shorter PFS compared with those without SMAD4 mutation (10m vs 16m, p¼0.035), while EGFR amplification did not impact PFS (17m vs 16m, p¼0.60). Conclusion: The efficacy of A+T combination was encouraging in the clinical practice and the PFS data 16m in the overall population is consistent with what observed in clinical trials. Patients with baseline brain metastasis & concomitant TP53 and EGFR amplification at progression benefited similar in PFS compared to those without these characters. T790M and MET amplification are the domain acquired resistance mechanism. SMAD4 mutation was regarded as novel resistance mechanism, with PFS shorter than 1 year. We will do a continuous observation on A+T combination in the real world. Reference 1, KATO T, et al. 2014 ASCO Abstract 8005#. 2, Furuya N, et al. 2018 ASCO Abstract 9006#. Keywords: Bevacizumab, EGFR-TKI, Acquired resistance, Next generation sequencing
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